Edward McGuire

RetroSense Therapeutics

Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel gene therapy approach to vision restoration. RetroSense is located in Ann Arbor, Michigan, a short drive from Wayne State University, where the approach was pioneered. RetroSense has secured exclusive, worldwide rights to relevant intellectual property from Wayne State University and Salus University. RetroSense uses channelrhodopsin-2, a photosensitivity gene / protein from blue-green algae. When administered to a degenerated retina, channelrhodopsin-2 restores light sensitivity and has restored functional vision to animal models of retinal degeneration. RetroSense's management team has commercial and scientific experience across all phases of drug development, as well as startup success. The Company operates virtually in order to secure top industry talent for its diverse, specialized needs in an efficient and effective manner. RetroSense is an agile company with a culture of flexibility, determination, and innovative thinking.